Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SOPHiA GENETICS (SOPH) Total Non-Current Liabilities (2020 - 2025)

SOPHiA GENETICS's Total Non-Current Liabilities history spans 6 years, with the latest figure at $65.4 million for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities rose 104.14% to $65.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $65.4 million, a 104.14% increase, with the full-year FY2025 number at $65.4 million, up 104.14% from a year prior.
  • Total Non-Current Liabilities hit $65.4 million in Q4 2025 for SOPHiA GENETICS, down from $65.8 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for SOPH hit a ceiling of $66.4 million in Q2 2025 and a floor of $8.0 million in Q2 2021.
  • Historically, Total Non-Current Liabilities has averaged $27.8 million across 5 years, with a median of $18.5 million in 2023.
  • The widest YoY moves for Total Non-Current Liabilities: up 125.7% in 2022, down 4.65% in 2022.
  • Tracing SOPH's Total Non-Current Liabilities over 5 years: stood at $16.2 million in 2021, then grew by 4.5% to $16.9 million in 2022, then grew by 12.99% to $19.1 million in 2023, then soared by 67.68% to $32.0 million in 2024, then surged by 104.14% to $65.4 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for SOPH at $65.4 million in Q4 2025, $65.8 million in Q3 2025, and $66.4 million in Q2 2025.